Last reviewed · How we verify

NCT03801512

Comparing the Efficacy of Steroid, Acupuncture and Platelet Rich Plasma Injection in Patients With Sciatica

Recruiting now NA Last updated 5 December 2024
What this trial tests

NA trial testing Steroid in Sciatica in 90 participants. Currently enrolling.

Timeline
24 April 2019
Primary endpoint
28 May 2025
28 May 2025

Quick facts

Lead sponsorTaipei Medical University Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment90
Start date24 April 2019
Primary completion28 May 2025
Estimated completion28 May 2025
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Taipei Medical University Hospital

Who can join

Adults 20 to 80, any sex, with Sciatica. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Disc herniation, stenosis of the spine and spondylolisthesis are the common causes of radiculitis in medical practice today, and can cause symptoms of sciatica. Steroid injection, acupuncture and platelet-rich plasma injection are often used interventions for the treatments of sciatica. The investigators will investigate the efficacy and safety of steroid injection, acupuncture and platelet-rich plasma injection for sciatica in this single center, parallel, randomized-controlled clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Steroid

Trials testing the same drug.

Other recruiting trials for Sciatica

Currently open trials in the same condition.

Other Taipei Medical University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03801512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing